Sometimes there are good news one comes across while doing the early morning snatch on news on the internet – news which just give this ray of hope. This one is certainly giving this ray of hope, even if success is still in the dark and not guaranteed. It’s about a vaccine, called SAV001-H, the result of a collaboration between Western University in London, Ontario, and Sumagen Canada Inc. In a randomized, observer-blinded, placebo-controlled study, the team examined the vaccine’s safety, tolerability and immune responses in HIV-positive adults between the ages of 18 and 50. And guess what: no significant adverse side effects discovered during trial period and researchers found that, following vaccination, the antibody against HIV’s p24 capsid antigen increased by a factor as great as 64 and the antibody against the virus’s gp120 surface antigen rose up to eightfold. These levels remained raised throughout the year-long study period.
This is good news on several layers: First of all there are people out there working on a vaccine and don’t give up. Second there will be now trial phase II. And there is an invitation attached: “We are opening the gate to pharmaceutical companies, government and charity organization for collaboration to be one step closer to the first commercialized HIV vaccine”, so Jung-Gee Cho, CEO of Sumagen.
Well, let’s support such efforts by all means possible. And if one is interested to read more on the subject click here.
- No adverse effects in volunteers following Phase I clinical trial of Sumagen AIDS vaccine (medicalnewstoday.com)
- New HIV Vaccine Proves Successful In Phase 1 Human Trial: Commercially Available Soon? (medicaldaily.com)
- New HIV Vaccines for People Who Aren’t Affected? (planet.infowars.com)
- HIV/AIDS vaccine passes Phase 1 clinical trial in humans (dvice.com)